Efficacy
tumor, colorectal cancer, HGG, RECIST, S3).For glioma, glioma, PD
GLIOMA, TUMOR, COLORECTAL CANCER, SOLID TUMOR
Ten patients were assessable for tumor response per investigator assessment, 9 with glioma (RANO criteria) and 1 with colorectal cancer (RECIST version 1.1); the other four enrolled patients withdrew from the study before the first tumor assessment. In the efficacy-evaluable population, the ORR was 20% (2/10), with all responses being PRs (Supplementary Table S3).For glioma, the best percent change in tumor size from baseline and the best response and time on therapy for patients with HGG are shown in Fig. 
Antitumor activity for patients with HGG. The other advanced solid tumor patient, a 49-year-old male patient with stage IV colorectal cancer, received standard regimens and developed PD. He was then enrolled in the 15-mg SYHA1813 group and achieved SD assessed on Cycle 1 Day 25, which had lasted 2 weeks by the study cutoff date.